Review Article USA
The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma
Published On: 2026-04-01 Authors: Priya Hays
Published On: 2026-04-01 Authors: Priya Hays
Published On: 2026-04-03 Authors: Mohammed Mustafa Hassan, Bashir Abdrhman Bashir
Published On: 2026-04-08 Authors: Georgia Kliampa, Theodora Douvali, Eleni Paparizou, Asimina Papadopoulou, Vasiliki Chasapi
Impact Factor:
* 3.5
Acceptance Rate:
71.36%
Time to first decision: 10.4 days
Time from article received to acceptance:
2-3 weeks
Discover More: Recent Articles
© 2016-2026, Copyrights Fortune Journals. All Rights Reserved!